Press Releases

Sangamo Announces Plans For New Headquarters In Brisbane, California

Company to transition to a dual site operating model with Point Richmond location retained as a Sangamo Research Center

RICHMOND, Calif., Nov. 9, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced plans for new corporate headquarters at 7000 Marina Boulevard, an 88,000 square foot building at Oyster Point in Brisbane, California, in the heart of the biotech hub south of San Francisco. Occupancy of the Brisbane site is expected in late 2018, after completion of architectural improvements. The Company will retain its Point Richmond location as a Sangamo Research Center.

Sangamo Therapeutics, Inc. (PRNewsFoto/Sangamo BioSciences, Inc.) (PRNewsFoto/)

In addition to laboratories, workstations and collaboration spaces, Sangamo will construct on-site in Brisbane a state-of-the-art, cGMP manufacturing facility to enable large-scale manufacturing of Sangamo's rapidly expanding pipeline of genomic therapies. Sangamo today separately announced improvements in its manufacturing and product development capabilities.

"Based on the progress we've made this year, our board of directors has encouraged us to be bold in planning for the company's successful future," said Sandy Macrae, CEO of Sangamo. "The new headquarters in Brisbane will provide a more competitive location and workspace, as we recruit the clinical, operational, manufacturing and management talent that we need to achieve our long-term goals. We intend to remain a top employer of scientists in the East Bay and are planning to update our Point Richmond facility as a Research Center for Sangamo."

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit

Forward Looking Statements
This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the expected timing of the completion of architectural improvements and relocation of Sangamo to its new headquarters, and the location providing better opportunities for recruiting talent. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, delays in or the inability to complete the build out of the new headquarters or in-house manufacturing capabilities, difficulties in recruiting talent to join the Sangamo team, as well as Sangamo's ability to retain its existing employee base as a result of the planned relocation.  In addition, Sangamo is subject to other risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.


View original content with multimedia:

SOURCE Sangamo Therapeutics, Inc.

Sign Up For E-Mail Alerts

Sign Up